Humacyte (HUMA) Shares Outstanding (2020 - 2026)
Humacyte (HUMA) posted quarterly Shares Outstanding (Entity) of $222.0 million for Q1 2026, up 43.13% year-over-year from $155.1 million in Q1 2025, and up 40.38% quarter-over-quarter from $158.2 million in Q4 2025.
Humacyte (HUMA) Shares Outstanding (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Shares Outstanding (Entity) for 7 consecutive years, with $222.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 43.13% year-over-year to $222.0 million; the TTM figure through Mar 2026 stood at $222.0 million (up 43.13% YoY), while the FY2025 annual figure was $158.2 million, up 21.64% from the prior year.
- Shares Outstanding (Entity) advanced to $222.0 million in Q1 2026 per HUMA's latest filing, from $158.2 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $222.0 million in Q1 2026 and bottomed at $103.0 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $127.4 million across 5 years, with a median of $119.1 million in 2024.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) soared 1966.4% — and 2023, when it grew 0.32%.
- Humacyte's Shares Outstanding (Entity) stood at $103.2 million in 2022, then gained by 0.43% to $103.7 million in 2023, then advanced by 25.42% to $130.0 million in 2024, then increased by 21.64% to $158.2 million in 2025, then surged by 40.38% to $222.0 million in 2026.
- Business Quant data shows HUMA's Shares Outstanding (Entity) at $222.0 million in Q1 2026, $158.2 million in Q4 2025, and $158.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.53 Bn | 130.68 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 86.34 Bn | 78.35 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.67 Bn | 59.48 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 59.04 Bn | 53.90 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.94 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.78 Bn | 27.47 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 27.81 Bn | 9.42 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.21 Bn | 26.05 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 26.99 Bn | 26.15 Bn | - | 445.06 Mn |
| 10 | Humacyte | 159.29 Mn | 159.29 Mn | -825,000.00 | 234.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 197.85 Mn |
| Mar 31, 2026 | 197.85 Mn |
| Dec 31, 2025 | 158.16 Mn |
| Sep 30, 2025 | 158.31 Mn |
| Jun 30, 2025 | 155.44 Mn |
| Mar 31, 2025 | 131.50 Mn |
| Dec 31, 2024 | 118.48 Mn |
| Sep 30, 2024 | 119.41 Mn |
| Jun 30, 2024 | 119.17 Mn |
| Mar 31, 2024 | 108.25 Mn |
| Dec 31, 2023 | 103.42 Mn |
| Sep 30, 2023 | 103.44 Mn |
| Jun 30, 2023 | 103.36 Mn |
| Mar 31, 2023 | 103.26 Mn |
| Dec 31, 2022 | 103.05 Mn |
| Sep 30, 2022 | 103.03 Mn |
| Jun 30, 2022 | 103.01 Mn |
| Mar 31, 2022 | 103.00 Mn |
| Dec 31, 2021 | 39.97 Mn |
| Sep 30, 2021 | 43.95 Mn |